항암제분류
|
|
|
- 지희 자
- 5 years ago
- Views:
Transcription
1 항암제의분류와약리작용 국립암센터약제부 전혜원
2 항암제의분류 Cytotoxic antineoplastics Alkylating agents Topoisomerase inhibitors Antimetabolites Microtubules inhibitors (Mitotic inhibitor) Hormonal agents Molecular targeted therapy Monoclonal Antibody Small molecule Immune therapy & Others.. in oncology Thalidomide, CTLA-4, PD-L1, and others
3 1. Cytotoxic antineoplastics
4 Cell cycle 과항암제의작용
5 1) Alkylating agents A. Nitrogen mustards Cyclophosphamide Ifosfamide Melphalan Chlorambucil Mechlorethamine B. Nitrosourea Carmustine Nimustine Lomustine Streptozocin C. Platinum analogues Cisplatin Carboplatin Oxaliplatin D. Others Ethylemines Thiotepa Alkylsufonate Busulfan Triazenes Dacarbazine Temozolomide
![1) Alkylating agents 작용기전 Formation of a positively charged ethylene immonium ion [-N-CH2CH2-] + => binds to electron rich nucleophilic sites](/docs-images/80/81483510/images/6-3.jpg "Cytotoxic effect Inhibition of DNA replication and transcription Mispairing of DNA Strand breakage Toxicity Myelosuppression Infertility Secondary")
6 1) Alkylating agents 작용기전 Formation of a positively charged ethylene immonium ion [-N-CH2CH2-] + => binds to electron rich nucleophilic sites Cytotoxic effect Inhibition of DNA replication and transcription Mispairing of DNA Strand breakage Toxicity Myelosuppression Infertility Secondary malignancy
7 Alkylating Agents A. Nitrogen mustards Cyclophosphamide Ifosfamide ( 사진 ) Melphalan Chlorambucil Mechlorethamine 적응증 NHL, HD, Leukemia, MM, BMT-conditioning, breast cancer, neuroblastoma and a variety other tumor Lung cancer, HD, NHL, Leukemia, breast cancer, testicular cancer, sarcomas MM, Ovrian cancer CLL, NHL, HD HD 부작용 Hemorrhagic cystitis N/V, alopecia, SIADH (> 50mg/kg), 2 nd malignancy, infertility Hemorrhagic cystitis (mesna 함께투여 )
8 Alkylating Agents B. Nitrosoureas 최근생산되는약제없음 적응증 부작용 Carmustine (BCNU) Brain tumor, HD, NHL, MM Delayed myelosuppression Severe N/V Pulmonary toxicity Nimustine (ACNU) Brain tumor, HD, NHL Delayed myelosuppression Lomustine (CCNU) Brain tumor, HD Delayed myelosuppression
9 Alkylating Agents C. Platinum analogues Cisplatin ( 사진 ) Carboplatin 적응증 Testicular cancer, ovarian cancer, head & neck cancer, lung cancer, esophageal cancer, cervical cancer, gastric cancer, or other cancers Ovarian cancer, lung cancer, bladder cancer, head & neck cancer, and testicular cancers 부작용 Severe nausea/vomiting (Acute, delayed) Nephrotoxicity; hydration Peripheral neuropathy Myelosuppression (Thrombocytopenia) Oxaliplatin 용량계산 : Calvert formula Dose=Target AUC x (CrCl+25) Colorectal cancer, gastric cancer Peripheral neuropathy (Cold triggered or aggravated)
10 Alkylating Agents D. Other alkylating agents Thiotepa 적응증 Breast cancer, ovary cancer, bladder cancer, lymphoma 부작용 Busulfan AML, CML, BMT Pulmonary toxicity (rare) Hyperpigmentation (High dose) Seizure, N/V, SOS Dacarbazine Melanoma, HD Nausea/Vomiting (N/V) Temozolomide ( 사진 ) Brain tumor N/V ( 취침전투약 ) ( 연하곤란환자 : 산성에서안정하므로사과쥬스에섞어서 L- tube 가능 )
11 2) Topoisomerase inhibitors Topoisomerase Regulation of DNA supercoiling Topoisomerase inhibitors 종류 Topoisomerase I inhibitor : Irinotecan, topotecan Topoisomerase II inhibitor : Anthracyclines, Epiphodophyllotoxins
12 2) Topoisomerase inhibitors Irinotecan( 사진 ), topotecan Topoisomerase I : DNA single strand breakage and religation, removal of supercoiling of DNA Topoisomerase I inhibitor: cleavable complex 상태로안정화시킴으로써 single stranded DNA break 를유도
13 2) Topoisomerase inhibitors Anthracycline, epipodophyllotoxins Topoisomerase II : DNA double strand cleaving and resealing, introduction of supercoiling in DNA Topoisomerase II inhibitor: preventing the ligation of DNA during replication Anthracycline Daunorubicin Doxorubicin ( 사진 ) Idarubicin Epirubicin Epipodophyllotoxins Etoposide Teniposide 작용기전 DNA intercalation Inhibition of Topoisomerase II free radical formation Inhibition of Topoisomerase II
14 2) Topoisomerase inhibitors 적응증 부작용 Daunorubicin Leukemia % Cardiotoxicity at Doxorubicin Cumulative Dose = 5% risk at 450 mg/m 2 Idarubicin Epirubicin Liposomal Doxorubicin ( 사진 ) Various solid tumors including breast cancer, ovarian caner lymphoma, leukemia Acute leukemia, lymphoma, HD Breast cancer AIDS-related Kaposi sarcoma, Multiple myeloma, advanced Ovarian cancer Cardiotoxicity, Palmarplantar erythrodysesthesia Etoposide Testicular cancer, Lung cancer Hypotension Teniposide HD, NHL, ALL, Bladder cancer Irinotecan Colorectal cancer, lung cancer Diarrhea (SN-38) Topotecan Ovarian cancer, SCLC
15 3) Antimetabolites 작용기전 Amino acid, DNA, RNA 등체내 natural compound 와구조적으로유사하여생합성시 enzyme 의 binding site 에서경쟁하거나 DNA 나 RNA 에 incorporation 되어 cytotoxic effect 를나타냄 분류 A. Folate antagonist B. Pyrimidine analogue C. Purine analogue
16 Antimetabolite A. Folate antagonist 작용기전적응증비고 Methotrexate (MTX) ( 사진 ) Dihydrofolate reductase (DHFR) 저해하여 thymidylate, purine 합성을저해 Triphoblastic neoplasm, leukemia, breast, head, lung cancer Mucositis, renal dysfunction, hepatotoxicity * Leucovorin rescue Pemetrexed Mutitargeted antifolate : TS, DHFR, GARFT 등효소모두저해 Malignant pleural mesothelioma, NSCLC Co-med: Folate, Vit B12, dexa
17 Antimetabolite Pemetrexed (Alimta ) Mutitargeted antifolate TS, DHFR, GARFT Co-medication 부작용을줄이기위해투여 (rash, myelosuppression) Folate mcg/day pemetrexed 투여 1 주일전부터투여종료 3 주후까지 Vit B mcg pemetrexed 투여 1 주일전부터 9 주간격으로 IM Dexamethasone 4mg bid, pemetrexed 투여전날, 투여당일, 투여다음날
18 Antimetabolite 20mg B. Pyrimidine analogue 25mg Cytarabine (Ara-C) Gemcitabine Fluorouracil (5-FU) Capecitabine ( 사진 ) TS-1 ( 사진 ) 작용기전적응증부작용 DNA polymerase를저해 Leukemia 고용량시 CNS toxicity, conjunctivitis Ribonucleotide reductase 를 저해, DNA incorporation Thymidylate synthetase (TS: dump dtmp ) 를저해 * leucovorin(folinic acid) 사용 5-FU 의 prodrug (3 단계를거쳐 5-FU 로변환, 마지막단계에서 Thymidine phsophrylase (TP) 에의해변환되는데이는정상조직보다암세포에서많음 ) Tegafur (5-FU prodrug), Gemeracil, Oteracil Pancreatic cancer, NSCLC Colon, breast, rectal, gastric, pancreatic cancer Colon, breast, rectal, gastric cancer Gastric, colon, rectal cancer Flu-like syndrome Diarrhea, skin discoloration Hand-foot syndrome Diarrhea Diarrhea, mucositis, Hand-foot syndrome Azacitidine Vidaza 골수이형성증후군 (MDS) N/V/D/C, HA, edema Decitabine Dacogen MDS 상동
19 Antimetabolite C. Purine analogue 작용기전적응증비고 Mercaptopurine (6-MP) Purine synthesis 저해 Leukemia Hepatotoxicity Thioguanine (6-TG) Guanine 과경쟁하여 purine synthesis 저해 Leukemia Hepatotoxicity Fludarabine DNA polymerase, ribonucleotide reductase 저해 CLL
20 4) Microtubule inhibitors 작용기전 Microtubule 의 polymerization, depolymerization 을억제하여 M- phase 세포분열을억제 Vinca alkaloids Tubulin 에결합하여 microtubule 을형성저해 Vincristine, vinblastine, vinorelbine 척수강내투여금기 Taxanes Microtubule 에결합하여 depolymerization 을저해 Paclitaxel, docetaxel
21 4) Microtubule inhibitors Vincristine 적응증 Leukemia, HD, neuroblatoma, lymphoma Neurotoxicity 부작용 Constipation, paralytic ileus Vinblastine HD, breast cancer, testicular cancer, Leukopenia, Neurotoxicity germ -cell tumor Thrombocytopenia Vinorelbine NSCLC, breast cancer Neurotoxicity, Constipation Docetaxel (Taxotere ) ( 사진 ) Paclitaxel (Taxol ) Ixabepilone (Ixempra ) Eribuline (Halaven ) Cabazitaxel (Zevtana ) Breast cancer, NSCLC, Ovarian cancer, Head & Neck cancer, gastric cancer Breast cancer, lung cancer, ovarian cancer, gastric cancer Breast cancer (± Xeloda ) Breast cancer hormone-refractory prostate cancer (+Prednisolone) Leukopenia, peripheral edema, alopecia, peripheral neuropathy, hypersensitivity Leukopenia, hypersensitivity, alopecia, peripheral neuropathy Leukopenia, peripheral edema, alopecia, peripheral neuropathy, N/V/D Leukopenia, alopecia, peripheral neuropathy Leukopenia, alopecia, peripheral neuropathy
22 문제 1. 다음중골수억제부작용이제일심각한약제는? A. Irinotecan B. Carboplatin C. Docetaxel D. Busulfan : alkylating agent, BMT
23 2. Hormonal agents
24 Hormonal therapy : breast cancer Premenopausal LHRH agonist Hypothalamus Pre / Postmenopausal LHRH X Pituitary ACTH FSH, LH Adrenal gland Ovary Androgen Estrogens Progesterone Antiestrogen X Aromatase inhibitor X X Estrogen
25 1) Antiestrogen: Tamoxifen 작용기전 Target specific action Antiestrogenic : breast, vagina, CNS Estrogenic : endometrium, bone, lipid SERM Tamoxifen( 사진 ) : 20mg/day 적응증 Hormone-positive breast cancer SERDs Fulvestrant : 500mg/q28day (IM) Toremifene : 60mg/day (FDA 2009) SERM : selective estrogen receptor modulator SERD : selective estrogen receptor downregulator 부작용 Hot flash, nausea, vaginal bleeding, thromboembolism, endometrial cancer
26 2) Aromatase inhibitor 작용기전 Estrone, estradiol 생성에작용하는 aromatase 를차단 Nonsteroidal Anastrozole ( 사진 ) : 1mg/day Steroidal Exemestane : 25mg/day Letrozole : 2.5mg/day 적응증 : Hormone-positive breast cancer, 폐경후 부작용 GI disturbance, hot flashes, Musculoskeletal symptoms, thromboembolic disorders
27 Hormonal therapy : Prostate cancer LHRH agonists Goserelin( 졸라덱스 *) Leuprorelin( 루크린 *) Triptorelin( 디페렐린 *) Produces ~10% of testosterone Orchidectomy ( 고환절제술 ) Produces ~90% of testosterone antiandrogen Antiandrogens Flutamide( 유렉신 *) Bicalutamide( 카소덱스 *)
28 3) LHRH agonist 작용기전 LH-RH analog 제제로서 pituitary gonadotropin secretion 억제 Goserelin (Zoladex ) Leuprorelin (Leucrin ) Triptorelin (Diphereline ) 3.6mg/q 1months 3.75mg/q 1months mg/q 3months 11.25mg/q 3months 11.25mg/q 3months - 30mg/q 6months - 적응증 Prostate cancer, breast cancer 부작용 Tumor flare (bone pain 등 ), Hot flashes, impotence, injection site reaction, bone loss
29 4) Antiandrogen 작용기전 Androgen receptor competitive inhibitor DHT receptor complex 형성을저해하여 androgen mediated action 을방해 종류 Flutamide, bicalutamide, nilutamide 적응증 : prostate cancer 부작용 Gynecomastia, hot flashes, GI disturbance(nausea, diarrhea), LFT 상승, visual disturbance
30 4) Antiandrogen Abiraterone acetate (Zytiga*) CYP17A1 의비가역적저해제 ( 고환, 부신, 전립선종양조직 ) 1000mg/day joint swelling or discomfort, hypokalemia, edema, Enzalutamide (Xtandi*) AR inhibitor 160mg/day Hot flush, hypertension, insomnia, edema, seizure... 이전에도세탁셀을포함한화학요법을받았던전이성거세저항성전립선암환자의치료
31 문제 2. 다음중 tumor flare 에대한우려없이단독요법으로사용가능한약제는? A. Degarelix B. Leuprolide C. Goserelin D. Triptorelin Firmagon is a GnRH receptor antagonist indicated for treatment of patients with advanced prostate cancer.
32 약제부고위험약물
33 약제부고위험약물
34 3. Molecular targeted therapy
35 Molecular targeted therapy R R Antibody-Based Membrane K K ATP Small Molecule Inhibitor Lung Prostate Breast Ovary Gastric Colon
36 Molecular targeted therapy (1) Mechanism of Action: 단클론항체 A~D 기전 A. 세포사멸 B. ADCC(Antibodydependent cellmediated cytotoxicity) C. 보체연쇄반응 D. 신생혈관생성억제
37 Targets Drugs Target HER CD20 CD30 CD33 CD52 VEGF Bcl-abl Multi- Monoclonal Abs Cetuximab, Panitumumab(HER-1) Trastuzumab,Pertuzumab,T-DM1(HER-2) Rituximab, Ibritumomab tiuxetan + Y-90 Tositumomab + I-131 Brentuximab Vedotin Gemtuzumab ozogamycin Alemtuzumab Bevacizumab, Ziv-aflibercept, Ramucirumab Tyrosine kinase inhibitor Gefitinib, Erlotinib, Lapatinib, Neratinib Imatinib Dasatinib, Nilotinib, Sunitinib, Sorafenib, Pazopanib, Regorafenib
38 Cetuximab (Erbitux ) Chimeric monoclonal antibody to EGFR EGFR(Epidermal Growth Factor Receptor) = HER 1, c-erbb-1 치료예측인자 = K-ras Ras gene ; wild type, Rash 적응증 Metastatic colorectal cancer (K-/N-Ras wild type) 부작용 Infusion-related reaction (20% 정도 ) hypersensitivity, skin rash, nausea, weakness
39 Trastuzumab(Herceptin ) Humanized monoclonal antibody to HER-2 HER-2 Human Epidermal growth factor Receptor-2 = HER2/neu, c-erbb-2 모든정상유방상피세포에서도 HER-2 발현하며정상 level 에서는유방의성장과발달을조절하는역할을함유방암환자의 20 30% 가 HER-2 과발현 HER2 과발현인유방암은특히더 aggressive 함 적응증 : HER-2 가과발현된유방암 (06 ), 위암 (10 FDA approval) 부작용 Infusion related reaction, Cardiac failure/dysfunction
40 Anti-VEGFs Bevacizumab (Avastin*) monoclonal antibody directed against vascular endothelial growth factor (VEGF) Ziv-aflibercept (Zaltrap*) Recombinant fusion protein; soluble receptor that binds to human VEGF-A, VEGF-B and P1GF Aflibercept VEGFR-1 IgG VEGFR-2 Fc
41 Bevacizumab (Avastin ) Humanized monoclonal antibody to VEGF VEGF(Vascular endothelial growth factor) 신생혈관형성촉진인자 VEGF-A 와결합 수용체에결합하지못하도록하여하여신생혈관형성 (angiogenesis) 을억제하여암의성장을막음 적응증 : metastatic colorectal cancer, breast ca., NSCLC 부작용 Hypertension, thromboembolism, abdominal pain, GI bleeding (GI perforation), weakness
42 Ramucirumab (Cyramza ) VEGF receptor-2 antagonist (human monoclonal antibody) VEGF receptor-2 를특이적으로결합해 VEGF receptor 인 VEGF-A, VEGF-C, VEGF-D 의결합을차단 적응증 : Gastric cancer(advanced or metastatic), Colorectal cancer(metastatic), Non-small cell lung cancer(metastatic) 부작용 Hypertension, Diarrhea, Decreased RBC (requiring transfusion; 11%), Headache, Proteinuria, Hyponatremia, Epistaxis, Skin rash, neutropenia, anemia, hemorrhage, Infusion related reaction ( 16%), Arterial thrombosis..
43 Rituximab (Mabthera ) Chimeric anti-cd20 IgG1 monoclonal antibody Killer leukocyte CD20 Malignant B cell Complement 적응증 Rituximab Rituximab Relapsed or refractory low-grade or follicular CD 20(+), B-cell NHL Diffuse large B-cell CD 20(+) NHL in combination with chemotx 부작용 Infusion related reaction, headache, asthenia
44 Brentuximab (Adcetris ) Chimeric monoclonal antibody to CD30 ADC (Ab-Drug Conjugate) 적응증 Hodgkins disease 부작용 Neutropenia, peripheral neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, vomiting
45 Trastuzumab emtansine (T-DM1) Herceptin + DM1 (microtubule inhibitor) ADC (Ab-Drug Conjugate) 적응증 HER2-positive, unresectable locally advanced or metastatic breast cancer 부작용 Nausea, Pain that affects the bones, muscles, ligaments, and tendons, Bleeding, Thrombocytopenia, Headache, Liver problems, Constipation, Nosebleeds Step 1 Step 2 Step 3 Step 4 Step 1: Kadcyla* attaches to a HER2 receptor Step 2: Kadcyla* goes inside the cell Step 3: Breaks apart inside the cell Step 4: Works to help kill the cell
46 Radioimmunotherapy MOA Ibritumomab (Zevalin ) Tositumumab (Bexxar ) Anti-CD 20 antibody linked to radioactive indium(in-111) and yttrium(y-90) Indication Relapsed or refractory CD20+ follicular NHL Side effect Infusion related reaction, thrombocytopenia, neutopenia, nausea, vomiting, weakness Anti-CD 20 antibody linked to radioactive Iodine (I 131) Infusion related reaction, thrombocytopenia, neutopenia, nausea, vomiting, anorexia, weakness, hypothyroidism
47 Molecular targeted therapy (2) Small molecules Tyrosine kinase inhibitors (TK inhibitors, TKI) 특징 Molecular target : 선택적, 부작용적음 경구섭취 : 복용간편 면역반응을유발하지않아장기투여로인한부작용적음 종류 Target HER Drugs Gefitinib(Iressa ), Erlotinib(Tarcevar ), Lapatinib, Neratinib Bcr-abl Imatinib(Gleevec ) Multi- Dasatinib, Nilotinib, Sunitinib, Sorafenib(Nexavar ) Pazopanib(Votrient ), Regorafenib (Stivagar ) ALK* Crizotinib (Xalcori ), Ceritinib (Zykadia ) * ALK: Anaplastic Lymphoma Kinase
48 Gefitinib (Iressa ), Erlotinib (Tarceva ) EGFR targeted- tyrosine kinase inhibitor 적응증 : NSCLC 부작용 Ligand EGF-Receptor (EGFR) Membrane EGFR-tyrosine Kinase (EGFR-TK) Acne-form rash, dry skin, diarrhea, Interstitial lung disease Proliferation Tissue invasion Angiogenesis Inhibition of apoptosis Disemination Metastasis
49 Crizotinib (XALKORI ) MOA EML4-ALK gene translocation ALK fusion protein cancer ALK inhibitor 적응증 ALK-positive metastatic NSCLC (FDA appraoval 2011) NSCLC 2~7% 부작용 vision disorder, N/V/D, edema, constipation
50 Ceritinib (Zykadia ) MOA EML4-ALK gene translocation ALK fusion protein cancer ALK inhibitor 적응증 ALK+ advanced NSCLC previously treated with crizotinib 부작용 Diarrhea, Hemoglobin decreased, Increase in liver enzymes, Nausea, Vomiting, Increase in creatinine, Abdominal pain
51 Dasatinib (Sprycel ) 작용기전 Potent multi-targeted tyrosine kinase inhibitor BCR-ABL, SRC family, c-kit, PDGFR- β Similar imatinib, but bind to both active and inactive conformation of BCR-ABL kinase domain 적응증 Ph+ CML in chronic, accelerated, blast phase with resistance or intolerance to prior therapy (imatinib) Ph+ ALL with resistance or intolerance to prior therapy (imatinib) 부작용 myelosuppression, diarrhea, fatigue, fluid retention
52 Imatinib (Glivec ) 작용기전 BCR-ABL tyrosine kinase 저해 BCR-ABL tyrosine kinase: CML 에서 Philadelphia chr translocation 에의해형성 c-kit, platelet-derived growth factor 저해 적응증 Ph+ CML in chronic, accelerated, blast phase Kit+ unresectable or metastatic GIST 부작용 myelosuppression, N/V, fluid retention, LFT 상승
53 Lapatinib (Tykerb ) 선택적으로 ErbB1 (EGFR) 과 ErbB2 (HER2) 를동시에억제 적응증 : Metastatic breast cancer capecitabine 또는 aromatase inhibitor 와병용 부작용 EGFR Diarrhea, Acne-form rash, hand foot syndrome Lapatinib (Tykerb ) Her2 neu
54 Nilotinib (Tasigna ) 작용기전 2 nd BCR-ABL inhibitor 적응증 이매티닙치료에저항성또는 불내성을보이는만성기또는가속기의필라델피아염색체양성만성골수성백혈병성인환자의치료 부작용 Myelosuppression, QT prolongation, serum lipase, hepatotoxicity ( bilirubin, AST/ALT, ALP), e abnormalities
55 Olaparib (Lynparza ) PARP inhibitor Inhibition of PARP-1~-3 적응증 Treatment (monotherapy) of BRCA mutated (as detected by an approved test) advanced ovarian cancer in patients who have been treated with 3 or more prior lines of chemotherapy 부작용 Peripheral edema, Myelosuppression, hypertension, fatigue, N/V/D PARP: Poly ADP-Ribose Polymerase
56 Olmutinib (Olita ) 작용기전 비가역적인변이형 EGFR 선택적억제제 (EGFR-MUTANT selective inhibitor) 로써, 정상형 EGFR 보다변이형 EGFR 에서보다강력한효소억제활성을나타냄 적응증 이전에 EGFR-TKI 로치료받은적이있는 T790M 변이양성국소진행성또는전이성비소세포폐암환자의치료 부작용 설사, 오심, 발진, 가려움증, 식욕저하, 피부건조, 손 - 발바닥홍반성감각이상증후군
57 Radotinib (Supect ) 작용기전 BCR-ABL tyrosine kinase inhibitor 적응증 필라델피아염색체양성만성골수성백혈병 (Ph+CML) 성인환자의치료 부작용 Bone marrow suppression: Thrombocytopenia, neutropenia, anemia, febrile neutropenia, pancytopenia Hepatotoxicity: hyperbilirubineia, ALT N/V, Headache, Musculoskeletal pain, Hyperglycemia, serum lipase, skin rash
58 Regorafenib (Stivarga ) Multi-targeted tyrosine kinase inhibitor Kit, PDGFR : Inhibition of proliferation, PDGFR-ᵝ,FGFR : inhibition of tumor microenvironement signaling, VEGFR-1~-3, Tie2 : inhibitions of angiogenesis 적응증 Gastrointestinal stromal tumors(imatinib, sunitinib 후재발 ) Metastatic colorectal cancer(anti-vegf therapy, or anti-egfr therapy (if KRAS wild type) 후재발 ) 부작용 Hypertension, Palmar-plantar erythrodysesthesia, lymphopenia, Proteinuria, N/VD
59 Pazopanib (Votrient ) Multi-targeted tyrosine kinase inhibitor 200mg, 400mg inhibits tumor growth via angiogenesis by inhibiting cell surface vascular endothelial growth factor receptors 적응증 advanced renal cell cancer (RCC) FDA approval advanced thyroid cancer, refractory metastatic soft tissue sarcomas Unlabeled use 부작용 Myelosuppression, hypertension, fatigue, N/V/D
60 Sorafenib (Nexavar ) Multi-targeted TK inhibitor Inhibition of Raf kinases (CRAF, BRAF, and mutant BRAF) Inhibition of cell surface kinase receptors (VEGFR-2, VEGFR-3, PDGFR-beta, ckit, and FLT-3) 적응증 advanced renal cell carcinorma hepatocelluar carcinoma 부작용 Hand-foot syndrome, hypertension, diarrhea, rash
61 Sunitinib (Sutene ) Multi-targeted tyrosine kinase inhibitor Platelet-derived growth factor receptor, vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), FMS-like tyrosine kinase-3 (FLT3), c-kit 적응증 GIST (Imatinib 요법에실패한경우 ) advanced renal cell carcinorma 부작용 Diarrhea, fatigue, fever, nausea, skin discolorization, hypertension, hand-foot syndrome, bleeding
62 문제 3. HER2-targeted drugs
63 4. Immune therapy & Others
64 Anti-cancer immunotherapy
65 Immune checkpoint 암세포는 T 세포의면역기능을억제하는리간드를과도하게발현하며, 이러한 T 세포를억제하는과정 PD-1/PD-L1 CTLA-4
66 CTLA-4 and PD-1 Pathways
67
68 Bortezomib (Velcade ) 작용기전 Proteasome inhibitor * Proteasome: Enzyme complex Velcade Responsible for degradation and activation of altered and regulatory proteins Cell Cycle Angiogenesis 적응증 Multiple myeloma 26S proteasome Apoptosis Myeloma cell interaction with microenvironment 부작용 Thrombocytopenia, neutropenia, N/V, peripheral neuropathy, fatigue
69 Thalidomide
70 Thalidomide 적응증 Newly-diagnosed Multiple myeloma 부작용 Drowsiness, somnolence, peripheral neuropathy, edema, skin rash, neutropenia, thromboembolic event 주의 최기형성에대한주의 : 피임필수 가임기 (4 주 ), 비가임기및남성 (8 주 ) 처방가능 최기형성에대한철저한관리를위해탈리도마이드위해관리프로그램 (TRMP) 에등록된의사, 약사만이처방및조제
71 Lenalidomide (Revlimid ) 적응증 Mantle cell lymphoma, Multiple myeloma, Del 5q Myelodysplastic Syndromes (MDS) 부작용 thrombocytopenia, neutropenia, drowsiness, edema, N/V/D/C peripheral neuropathy, skin rash 주의 CLcr<30ml/min 투석환자 30 CLcr <50ml/min CLcr <30ml/min 비투석환자 (48 시간마다 ) 최기형성에대한주의 : 피임필수 가임기 (4 주 ), 비가임기및남성 (8 주 ) 처방가능 최기형성에대한철저한관리를위해레날도마이드위해관리프로그램 (REMS) 에등록된의사, 약사만이처방및조제
72 mtor inhibitor 작용기전 targeted inhibitors of mtor (mammalian target of rapamycin) kinase activity Cell proliferation Angiogenesis Cell metabolism
73 mtor inhibitor 약제 Temsirolimus (Torisel ) Everolimus (Afinitor ) 적응증 Advanced renal cell carcinoma 부작용 Rash, stomatitis, edema, anemia, hypertension, abn. hepatic func. hyperlipidemia
74 문제 4. 다음항암제중 in-line-filter 를사용하여투약하지않아도되는약제는? A. Paclitaxel B. Cabazitaxel C. Nivolumab D. Temsirolimus E. Trastuzumab (IV) E. Trastuzumab (IV) F. Trastuzumab emtansine (T-DM1)
75 Anticancer drugs-filter set 항암제 Blinatumumab Cabazitaxel Nivolumab Paclitaxel Pembrolizumab 구분 무균, 비발열성, 저단백질결합인라인필터 (0.2 마이크론 ) ( 탁솔필터안됨 - 암젠 ) 탁솔필터 무균, 비발열성, 저단백질결합인라인필터 (0.2~1.2) ( 탁솔필터안됨-오노제약 ) ( 허가가항변경 ) 0.22-micron in-line filter and polyethylene-lined (non-pvc) administration set 한국엠에스디제공 : 0.2 to 5 micron sterile, nonpyrogenic, low-protein binding inline or add-on filter Ramucirumab 탁솔필터 ( 필수아니고권장사항 - 한국릴리 ) Temsirolimus Thiotepa 화이자제공 : polyethylene-lined non-dehp administration tubing and a polyethersulfone end filter (0.2 to 5 micron) 탁솔필터 Trastuzumab emtansine 탁솔필터
76 경청해주셔서감사합니다. euri@ncc.re.kr
<B0E6C8F1B4EBB3BBB0FA20C0D3BBF3B0ADC1C E687770>
2012 개원의와함께하는임상강좌 경희대학교의과대학종양혈액내과학교실 백선경 한국인사망원인 평균수명까지생존시암발생확률 길라잡이 : 개정된가이드라인을중심으로 History of anti-cancer chemotherapy Chabner BA & Roberts TG Jr. Nat Rev 2005 Use standard therapies 2012 개원의와함께하는임상강좌
<30352DB1E8C0AFC1A42DC6EDC1FD2DBDBD2E687770>
Introduction to Medical Oncology and Molecularly Targeted Therapy 서울대학교의과대학내과학교실분당서울대학교병원혈액종양내과 김유정 연도별성별암발생자수추이 70 분당서울대학교병원 제 8 회분당서울대학교병원내과연수강좌 2012 평균수명까지생존시암발생확률, 2009 주요암종발생분율, 2009 분당서울대학교병원 71
<4D F736F F F696E74202D DBFACBCF6B0ADC1C22DC7A5C0FBC4A1B7E12DC0CCB1D9BFED2DBFF8B0ED2E BC8A3C8AF20B8F0B5E55D>
2008.8.31. 내과연수강좌 표적치료제의 허와실 - 항암치료의최신동향- 분당서울대학교병원혈액종양내과이근욱 Treatment of Cancer 1890-1980s 1990s 2000s Surgery Radiotherapy Chemotherapy Biologic therapy Gene therapy? Target-based Therapy Most Anticancer
Introduction 한국인에서암은지난 10 년간사망원인 1 위였으며, 암발생은지속적으로증가추세에있다. 최근암조기발견과암치료의발전으로암생존율이향상됨에따라생존기간뿐아니라암치료에의한장기적영향과생존자의삶의질에대한관심이높아지고있다. 한국인의주요암의 5 년상대생존율 : 46.
항암치료의이해 순천향대학교병원 종양혈액내과박희숙 Introduction 한국인에서암은지난 10 년간사망원인 1 위였으며, 암발생은지속적으로증가추세에있다. 최근암조기발견과암치료의발전으로암생존율이향상됨에따라생존기간뿐아니라암치료에의한장기적영향과생존자의삶의질에대한관심이높아지고있다. 한국인의주요암의 5 년상대생존율 : 46.3% (2002 년 ) 2 우리나라암발생률,
11³â6¿ùTiBMB_±è¹Ì°æ
TiBMB- Antibody Therapy 치료용 항체-약물 결합체 (antibody-drug conjugate)의 개발 동향 김미경 김상윤 강원대학교 시스템면역과학과 서울대학교 의생명과학대학 의과대학 신경과학교실 분당서울대학교병원 뇌신경센터 kmkim@kangwon.ac.kr 1. 서론 항체 개발에도 많은 연구가 적극적으로 진행 중이다. 차세 대 항체, 즉
한약치료와표적항암요법 ( 아피니토 ) 을병행하여부분관해된신세포암간전이환자 1 례 Abstract Sung-Hwan Chang 1, Ji-Hye Park 1,2, Hwa Seung Yoo,2*
https://doi.org/10.15432/jkto.2017.22.2.013 한약치료와표적항암요법 ( 아피니토 ) 을병행하여부분관해된신세포암간전이환자 1 례 Abstract Sung-Hwan Chang 1, Ji-Hye Park 1,2, Hwa Seung Yoo,2* 1 JangDeuk Integrative Medical Center, Korean Medicine
Δ Epidermal growth factor receptor (EGFR) is well established target for cancer treatment and EGFR tyrosine kinase (TK) inhibitors such as gefinitib and elotinib have been developed as anti-cancer drugs.
2016 학년도약학대학면접문제해설 문제 2 아래의질문에 3-4분이내로답하시오. 표피성장인자수용체 (epidermal growth factor receptor, EGFR) 는수용체티로신인산화효소군 (receptor tyrosine kinases, RTKs) 의일종으로서세
본문제에대한지적소유권은동국대학교에있습니다. 본교의서면허락없이무단으로출판, 게재, 사용할수없습니다. 문제 2 2016 학년도약학대학면접문제 아래의질문에 3-4 분이내로답하시오. 표피성장인자수용체 (epidermal growth factor receptor, EGFR) 는수용체티로신 인산화효소군 (receptor tyrosine kinases, RTKs) 의일종으로서세포의생존과증식
오심/구토-부인암 항암화학요법
Managements of CINV (Chemotherapy Induced Nausea and Vomiting) 삼성서울병원부인암센터부인종양전문간호사김상희 Objectives CINV 의분류 CINV 의위험인자구토유발정도에따른항암제의분류 CINV 발생기전항구토제 CINV 치료의표준지침 Introduction One of the most distressing
기관고유연구사업결과보고
기관고유연구사업결과보고 작성요령 2001 ~ 2004 2005 ~ 2007 2008 ~ 2010 2001 ~ 2004 2005 ~ 2007 2008 ~ 2010 1 2/3 2 1 0 2 3 52 0 31 83 12 6 3 21 593 404 304 1,301 4 3 1 8 159 191 116 466 6 11 (`1: (1: 16 33 44 106
PowerPoint 프레젠테이션
Apr. 30. 2016. GBCC in JeJu Island Sensitization of breast cancer cells to chemotherapeutic drugs by metabolic regulation InChul Park, Ph. D. Korea Institute of Radiological & Medical Sciences (KIRAMS)
Mol_Imaging
Molecular Imaging & Molecular Targeted Therapy 서울대학교의과대학핵의학교실 팽진철 1. 분자영상 분자영상의개념 영상표적화기법 추적자및영상기법 Molecular Imaging ( 분자영상 )? In Wikipedia - Molecular imaging is a new discipline that unites molecular
Pharmacotherapeutics Application of New Pathogenesis on the Drug Treatment of Diabetes Young Seol Kim, M.D. Department of Endocrinology Kyung Hee Univ
Application of New Pathogenesis on the Drug Treatment of Diabetes Young Seol Kim, M.D. Department of Endocrinology Kyung Hee University College of Medicine & Hospital E mail : ycell2@yahoo.co.kr Abstract
550호(01-09)
T H E K O R E A N D O C T O R S W E E K L Y www.docdocdoc.co.kr I N S I D E 38 3 5 6 8 11 13 24 25 27 29 31 38 41 42 2 Advertisement Government & Medicine 3 Government & Medicine 4 Government & Medicine
항암치료의원칙및 심사기준 순천향대학교병원 종양혈액내과박희숙
항암치료의원칙및 심사기준 순천향대학교병원 종양혈액내과박희숙 암치료의목표 일차목표 : to eradicate the cancer( 암제거 ) 일차목표가불가능한경우 (Palliation, 완화요법 ) 진행방지 ( SD PR CR) 증상의완화생명연장삶의질개선 ( 통증완화등 ) 항암치료 수술 방사선치료 항암화학요법 세포독성치료 면역요법 생물학적치료 유전자요법 대체요법
권두칼럼 조찬휘 대한약사회장 회원의 손톱 밑 가시 뽑는 소통, 국민에게 신뢰 주는 커뮤니케이션 대한약사회장 조 찬 휘 커뮤니케이션의 어원적 정의는 공유, 공통, 나누어갖다 등으로 되어 있습니다. 커뮤니케이션은 언어나 몸짓, 화상 등의 물질적 기호를 매개수단으로 하는 정
CONTENTS 권두칼럼 발언대 인터뷰 업체탐방 캠페인 02 04 06 10 14 회원의 손톱 밑 가시 뽑는 소통, 국민에게 신뢰 주는 커뮤니케이션 조찬휘 대한약사회장 약사 직역 향상은 약계 상생 및 생존 전략에 달려있다 손의동 대한약학회장 의약분업 시행 초기 미비된 환경 정비하고 약국경영 안정화에 최선을 다했다 한석원 전 대한약사회장 R&D 중심기업 한미약품을
항암치료란.ppt [호환 모드]
![항암치료란.ppt [호환 모드]](/thumbs/94/118189361.jpg "항암치료란.ppt [호환 모드]")
암! 알아야이겨낼수있죠! - 항암치료란? - 한림대학교성심병원 혈액종양내과 암? 도대체왜? 암의두가지큰특징 1) 정상적인범위를벗어나끊임없이세포분열을하고성장 - 양성및악성종양 2) 다른세포가차지하고있는고유영역을침범함 - 악성종양 대부분의암은한개의비정상세포로부터 알수가없어요? 암전이의단계 조기발견할경우암의 5년생존율 유방암 : 95% (0 기암 : 100%)
PowerPoint Presentation
제 7 회페루자국제암회의 항구토요법지침 (2008 년 3 월최신개정 ) BASED ON: THE CONSENSUS CONFERENCE ON ANTIEMETIC THERAPY* 한국호스피스완화의료학회 * Conference conducted in March 2004 MASCC (Multinational Association of Supportive Care in
<303220C6AFC1FD20BCDBB0E6C8A D E687770>
대한내과학회지 : 제 82 권제 5 호 2012 http://dx.doi.org/10.3904/kjm.2012.82.5.532 특집 (Special Review) - 구역과구토 (nausea and vomiting) 항암치료중구역과구토의처치 건양대학교의과대학내과학교실 송경호 Management of Chemotherapy Induced Nausea and Vomiting
Microsoft PowerPoint - 김미영
암세포의위험한여행 한국과학기술원 김미영 강의개요 전이란무엇인가? 전이는어떤과정을통해진행될까? 전이예측방법은어떤것들이있을까? Cancer ( 악성종양 ) US South Korea 질병사망률질병사망률 1. 심장병 26% 1. Cancer 26.7% 2. Cancer 23% 2. 뇌출혈 12.7% 3. 뇌출혈 5.6% 3. 심장병 7.9% >20,000 환자가악성종양에의해매일사망함
0806ksco 4호.ps, page Normalize
References : 1. ATAC Completed Treatment Analysis: Anastrozole demonstrates superior efficacy and tolerability compared with tamoxifen. Howell A on behalf of the ATAC Trialists Group San Antonio 2004.
<313020BFF8C0FA203030373320B1E8BACEB0E62E687770>
대한내과학회지: 제 80 권 제 6 호 0 진행성 위암에 대한 차 요법으로 Docetaxel, Cisplatin, 5-FU 복합화학요법의 효과와 안전성 고신대학교 의과대학 내과학교실 김부경 박무인 박선자 김규종 문 원 정수현 김혜수 남성진 Docetaxel, Cisplatin, 5-FU Combination Chemotherapy as a First-Line
항암치료와탈모 저자최선서울성모병원약제부입원조제 UM 약학정보원학술자문위원 개요 항암치료를받는환자들에게흔히나타나는부작용중하나가탈모이다. 탈모는치명적인부작용은아니지만외모에대한영향으로인해치료를거부하는주요원인중하나로작용하곤한다. 이에탈모를유발하는주요항암제에대한정보를알아보고,
항암치료와탈모 저자최선서울성모병원약제부입원조제 UM 약학정보원학술자문위원 개요 항암치료를받는환자들에게흔히나타나는부작용중하나가탈모이다. 탈모는치명적인부작용은아니지만외모에대한영향으로인해치료를거부하는주요원인중하나로작용하곤한다. 이에탈모를유발하는주요항암제에대한정보를알아보고, 항암치료에따른탈모의예방이나관리방법에대해알아보고자한다. 키워드 항암치료, 탈모 1. 항암치료유발탈모의개요
Molecular Classification of Breast Cancer
혈액종양내과분과연수강좌 2011 Advances in treatment strategies Breast Cancer 연세의대내과학교실 손주혁 Molecular Classification of Breast Cancer Issues Adjuvant taxanes Avoiding adjuvant chemotherapy Anthracyclines in EBC Adjuvant
표적치료제의모든것소분자키나제억제제 (1) 저자최병철 약학정보원학술자문위원 머리말 소분자키나제억제제 (small molecule kinase inhibitor) 는신호전달경로 (signal transduction pathway) 를표적으로하므로넓은의미로는신호전달경로억제제
표적치료제의모든것소분자키나제억제제 (1) 저자최병철 약학정보원학술자문위원 머리말 소분자키나제억제제 (small molecule kinase inhibitor) 는신호전달경로 (signal transduction pathway) 를표적으로하므로넓은의미로는신호전달경로억제제라고한다. 소분자키나제억제제는모두경구제로서, 2001년최초로승인된 BCR-Abl 티로신키나제억제제
untitled
Systemic Treatment of Pancreatic Neuroendocrine Tumors 장흥문 울산대학교의과대학서울아산병원종양내과학교실 췌장에생기는신경내분비종양 (pancreatic neuroendocrine tumor: PNET) 은매우드문종양으로주로췌장의 islets of Langerhans 에서발생하므로 islet cell tumor라고도부른다.
Kaes010.hwp
갑상선자극호르몬이갑상선암세포의 VEGF, 신생혈관형성, 성장, 침윤및전이에미치는영향 Effects of TSH on the Production of VEGF, Angiogenesis, Growth, Invasion and Metastasis in Thyroid Cancer Cells Euy Young Soh, M.D., Hee Boong Park, M.D.,
종양 혈액암 ( 종양 ) (Hematlogic Malignancies) 양성종양 악성종양 악성종양 ( 질환 ) 암 고형암 : 고형장기발생악성질환 혈액암 : 골수또는림프조직에서발생
혈액암 (Hematologic Malignancy) 경희대학교병원종양혈액내과 조경삼 종양 혈액암 ( 종양 ) (Hematlogic Malignancies) 양성종양 악성종양 악성종양 ( 질환 ) 암 고형암 : 고형장기발생악성질환 혈액암 : 골수또는림프조직에서발생 혈액암 분류 : 형태학, 임상소견 백혈병 악성림프종 형질세포질환 골수이형성증후군 만성골수증식성질환
7.ƯÁýb71ÎÀ¯È« š
J KMA Special Issue Myelodysplastic Syndrome June Won Cheong, MD Yoo Hong Min, MD Department of Internal Medicine, Yonsei University College of Medicine E mail : jwcheong70@yumc.yonsei.ac.kr minbrmmd@yumc.yonsei.ac.kr
PowerPoint 프레젠테이션
Treatment of Breast Cancer Hee Sook Park M.D. Division of Hematology/Oncology Soon Chun Hyang University Hospital 유방암의빈도 Worldwide Estimate - 1,050,000 new cases - 205,000 breast cancer related death In
Microsoft PowerPoint Free Papers (Abstracts)12.ppt
고혈압을동반한전립선비대증환자에서 doxazosin 4mg 투여후효과가부족한경우에서 doxazosin 8mg 용량증가와 doxazosin 4mg + tamsulosin 0.2mg 병합요법비교 조인래, 김종구, 이건철 인제대학교일산백병원비뇨기과 고혈압환자에서알파차단제투여시일반적기준 전립선비대증 + 고혈압 합병증이있는고혈압 단순고혈압 α 차단제투여 내과의사 Antihypertensive
7월웹진
최근연구소식 최근의연구동향을이해할수있도록몇편의논문을요약하여하나의주제로소개합니다. 새로운항암치료타겟인 c-met 저해제의연구현황 Livio Trusolino, Andrea Bertotti and Paolo M. Comoglio (2010) MET signalling: principles and function in development, organ regeneration
Treatment and Role of Hormaonal Replaement Therapy
Treatment and Role of Hormone Replacement Therapy Chung-Ang University Hospital Chee Jeong Kim 7.2 5.3 6.4 5.6 7.3 5.5 1 1 2 3 4 10 11 7 34 49 122 123 1.0 - - 10. 2001 1998 1998 Improvement of postmenopausal
<B0E6C8F1B4EBB3BBB0FA20C0D3BBF3B0ADC1C E687770>
2012 개원의와함께하는임상강좌 경희대학교의과대학감염내과학교실 문수연 F/29 CC: fever, headache, multiple cervical lymph node onset) 5 days ago 1 cm sized Bilateral, mild tender, movable, soft Reactive LN with viral infection 2012 개원의와함께하는임상강좌
00약제부봄호c03逞풚
경희대학교 동서신의학병원 약품 정보지 2 0 0 7. S P R I N G. V O L. 0 1 신약 소개 02 Journal Review 03 Special Subject 04 복약 지도 06 의약품 안전성 정보 07 약제부 알림 07 약제부 업무 소개 08 E A S T - W E S T N E O M E D I C A L C E N T E R 본 약품
삼성전자 (005930)
제넥신 (095700) 2018/02/21 빅파마의경쟁구도관점에서본하이루킨 제약 / 바이오허혜민 (2122-9183) hyemin@hi-ib.com Nektar 와 BMS 의계약이시장에던지는의미 BMS 는 Nektar 의 NKTR-214( 인터루킨 -2) 단일약물로만최대 36 억달러 ( 약 4 조원 ) 의글로벌공동개발계약을맺었다. BMS 가보유하고있는면역관문억제제
Jkbcs016(92-97).hwp
Expression of bcl-2 and Apoptosis and Its Relationship to Clinicopathological Prognostic Factors in Breast Cancer - A Study with Long Term Follow-up correlated with the survival rate.(journal of Korean
Targeted Therapy for Breast Cancer 113 있고, 이 HER2 단백이과발현되어있는유방암환자가그렇지않은환자보다예후가불량한것으로보고되었고 [3] 이에대한표적치료제의가능성이꾸준히제시되어오던중, 1998 년에 HER2 단백의 extracelluar
![Targeted Therapy for Breast Cancer 113 있고, 이 HER2 단백이과발현되어있는유방암환자가그렇지않은환자보다예후가불량한것으로보고되었고 [3] 이에대한표적치료제의가능성이꾸준히제시되어오던중, 1998 년에 HER2 단백의 extracelluar](/thumbs/81/84378214.jpg "Targeted Therapy for Breast Cancer 113 있고, 이 HER2 단백이과발현되어있는유방암환자가그렇지않은환자보다예후가불량한것으로보고되었고 [3] 이에대한표적치료제의가능성이꾸준히제시되어오던중, 1998 년에 HER2 단백의 extracelluar")
112 Hanyang Medical Reviews Vol. 32, No. 2, 2012 http://dx.doi.org/10.7599/hmr.2012.32.2.112 유방암의표적치료 Targeted Therapy for Breast Cancer 오호석울산의대강릉아산병원내과학교실 Ho-Suk Oh, M.D., Ph.D. Department of Internal
( )Jkstro011.hwp
비인강암의방사선치료결과및생존율에관한예후인자분석 2005 2 1 2005 3 28. :, Tel: 053)250-7665, Fax: 053)250-7984 E-mail: jhkim@dsmc.or.kr 정영연외 2 인 : 비인강암의예후인자분석 정영연외 2 인 : 비인강암의예후인자분석 Carcinoma of the nasopharynx treated by radiotherapy
02-윤호중ok
REVIEW ARTICLE Chemotherapy induced Cadiotoxicity 항암제 심독성 Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea Ho-Joong Youn, M.D.
Kaes017.hwp
갑상선의 Poorly Differentiated (Insular) Carcinoma Insular Carcinoma: An Aggressive Subtype of Differentiated Thyroid Neoplasms Seok-Jin Nam, M.D., Sang-Dal Lee, M.D., Hal-lin Park, M.D., Young-Ryun Oh, M.D.
<28C3D6C1BEB3BBC1F629BECFC8AFC0DAC3B3B9E6C5F5BFA9C7CFB4C2BEE0C1A6BCBCBACEBBE7C7D E E687770>
발간등록번호 G000J67-2016-102 암환자에게처방 투여하는약제에대한 요양급여의적용기준및 방법에관한세부사항 2016. 11. 건강보험심사평가원공고제 2016-282 호 제정 2006.1.9 공고제2006-1호 (2006.1.9 시행 ) 개정 2006.2.1 공고제2006-2호 (2006.2.1 시행 ) 개정 2006.3.31 공고제2006-3호 (2006.4.1
Chapter 26
11 주 RNA 합성 11.1 DNA-dependent synthesis of RNA: Bacteria에서의 transcription l RNA polymerase (5 subunits로구성 : 2α, β, β, σ) l 효소에의한 RNA 합성의특징 - Complementary sequence to template DNA - RNA chain의합성방향 : 5
factor receptor, EGFR) 에대한연구가시작되면서부터이다. 이후 kinase inhibitor들의약리학적특성에대한수많은연구결과가발표되었으며, 이계열약물개발이계속되어최근 2018년 Bhullar et al등의발표자료에따르면미국 FDA에서승인받은 kinase
Tyrosine Kinase inhibitors 저자최선가톨릭중앙의료원연구윤리사무국피험자보호팀장약학정보원학술자문위원 개요 Tyrosine kinase inhibitor(tki) 는인류가정복해야할질병중부동의 1위를차지하고있는암에대한선택적치료능력을갖추어표적치료제혹은 2세대항암치료제로도알려져있다. 실제로 2000년대초반최초의 TKI인 imatinib이개발된후로암환자의치료는괄목할만한발전을보였다.
OvCa guideline ( )
Practice Guideline for Gynecologic Cancer v 2.0, 2010 Ovarian Cancer Guideline Tae Joong, Kim Department of OB/GYN Samsung Medical Center Sungkyunkwan Univ. School of Medicine : : :,,,, :,,,,,,,,,, :,,,,
ÀÇÇа�ÁÂc00Ì»óÀÏ˘
Common Allergic Diseases in Children Sang - Il Lee, M.D. Department of pediatrics Sungkyunkwan University School of Medicine, Samsung Medical Center E - mail : silee@smc.samsung.co.kr Abstract Allergy
Microsoft Word _Issuenpitch 한미약품_ 폐암 기술수출_dU753SmbJKJbI1XAP3b5
Issue & Pitch 대한항공 () 한미약품 (12894) 표적항암제추가기술수출, 주가에는기반영 Jul. 215 29 Analyst 이혜린 2) 2184-2327 / hrin@ktb.co.kr Hold 현재직전변동투자의견 Hold 유지 목표주가 53, 유지 Earnings 유지 Stock Information 현재가 (7/28) 545, 원 예상주가상승률
2015년 3주차 바이오산업동향(150119).hwp
주요 바이오산업 동향 (1.12~1.16 : 2015-3주차) Biotech 기업 동향 CJ헬스-대웅, 당뇨+고지혈증 복합약 공동개발키로 (1.12, 머니투데이) ㅇ CJ헬스케어(대표 곽달원)는 대웅(대표 정난영)과 메트포르민, 아토바스타틴 성분의 당뇨-고지질혈증 치료 복합제의 공동개발 계약을 체결했다고 12일 밝혔다. 이번 계약에 따라 CJ헬스케어는 임상1상
<28B3BBC1F6C3D6C1BE29BECFC8AFC0DABFA1B0D420C5F5BFA9C7CFB4C220BEE0C1A6BCBCBACEBBE7C7D75F E687770>
건강보험심사평가원공고제 2017-260 호 제정 2006.1.9 공고제2006-1호 (2006.1.9 시행 ) 개정 2006.2.1 공고제2006-2호 (2006.2.1 시행 ) 개정 2006.3.31 공고제2006-3호 (2006.4.1 시행 ) 개정 2006.4.28 공고제2006-4호 (2006.5.1 시행 ) 개정 2006.5.29 공고제2006-5호
Çмú°�Á½ÅÁö¿¬
병원약사회지 (2015), 제 32 권제 4 호 J. Kor. Soc. Health-Syst. Pharm., Vol. 32, No. 4, 341 ~ 348 (2015) 학술강좌 새로운기전의유방암치료제 : Palbociclib 신지연 a, 윤현옥 a,b 경상대학교약학대학약학과 a, 경상대학교약학연구소 b 유방암은세계적으로전체여성암의약 20% 를차지하고한국에서도여성암
Jkbcs032.hwp
Clinical Correlation of HER-2/neu Overexpression in Patients with Breast Cancer Sung Yong Kim, Tae Yoon Kim, Jae Jun Kim, Chang Ho Kim, Ok Pyung Song, Min Hyuk Lee, Eui Han Kim 1, and Moo Sik Cho Departments
Chapter 14
5 주 Gycoysis 5.1 Gycoysis의일반적특징 Gycoysis - Gucose가 degradation 과정을거쳐두개의 pyruvate를형성하는과정. - 이때발생하는 free energy는 ATP와 NADH로보존됨. - Gucose 2 Pyruvate - ADP phosphoryation을통하여, ATP 형성 - NAD + 로 hydride ion
김범수
Analysis of Outcomes after Resection of Sarcomatous Hepatocellular Carcinoma Purpose: Sarcomatous hepatocellular carcinoma (HCC) is rare. Therefore, the clinicopathologic characteristics and prognosis
l l l l l l l l l Lee, Geon Kook None This project was designed to establish the Tumor Bank of National Cancer Center in 2000. From the first tumor sample in 2000, the total of tumor and tumor-related
untitled
대한내과학회지 : 제 71 권부록 2 호 2006 임상강좌 Role of Radiotherapy in Induction CCRT 연세대학교의과대학방사선종양학교실 서창옥 기존에여러종류의암에적용되고있는방사선치료의효과를높이기위하여정상조직에는보다적은선량을조사하면서종양에는보다많은방사선량을조사하는기술적혁신과함께방사선에의한생물학적반응을조절하는여러방법들이시도되어왔다. 그중에서항암제를방사선치료와병행하는방법이가장큰효과를보이고있다.
부.울.경 소화기내시경 집담회
부. 울. 경 소화기내시경집담회 2014.05.07 고신대학교복음병원소화기내과전임의한유진 CASE 55/M C/C Hematemesis for 1day P/I #2014.3.11 whole body rash with itching sense #3.25 Bullous pemphigoid dermatology #3.26 po steroid start #4.4 po
Novartis Sample Deck for Externals
항암약물치료 Recent Clinical Data Review -Gastric Cancer (Anticancer Systemic Treatment) Do-Youn Oh, MD., PhD. Medical Oncology, Seoul National University Hospital Cancer Research Institute, Seoul National University
<303420C1BEBCB320BDC9BCB1C1F82E687770>
대한내과학회지 : 제 89 권제 5 호 2015 http://dx.doi.org/10.3904/kjm.2015.89.5.515 종설 (Review) 진행성방광암의항암화학요법 가천대학교길병원혈액종양내과 심선진 Systemic Treatment for Metastatic Bladder Cancer Sun Jin Sym Division of Hematology and
<30332EBABBB9AE2E687770>
간세포암에서의표적치료 울산대학교의과대학서울아산병원내과 이한주 Targeted therapy in hepatocellular carcinoma Han Chu Lee, M.D. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
<303520C1BEBCB320B1E8B5BFBFED203731382D3732332E687770>
대한내과학회지: 제 83 권 제 6 호 2012 http://dx.doi.org/10.3904/kjm.2012.83.6.718 종 설(Review) 만성골수성백혈병의 최신동향 가톨릭대학교 서울성모병원 혈액내과 김 동 욱 Recent Advances of Management for Chronic Myeloid Leukemia Dong-Wook Kim Department
06. Roadmap to final diagnosis.hwp
대한내과학회지 : 제 93 권제 3 호 2018 https://doi.org/10.3904/kjm.2018.93.3.266 Roadmap to diagnosis 분자생물학적기법에근거한비편평상피세포폐암의진단과치료 고려대학교의과대학구로병원호흡기내과 이승룡 Diagnosis and Treatment of Non-Squamous Lung Cancer Based on
노영남
Purpose: Delayed massive hemorrhages from pseudoaneurysm rupture of the peripancreatic large arteries, after pancreaticoduodenectomy, are fatal. We reviewed the clinical course and outcome of bleeding
untitled
간암치료에서 Molecular Target Agents 의역할 최종영 가톨릭대학교의과대학서울성모병원소화기내과 요약 Sorafenib은 RAF, VEGF, PDGF, Flt-3, c-kit receptor typrosine kinase inhibitor로서간암세포증식과신혈관생성을억제하는기능을가지고있어 2007년에미국 FDA에서간암, 신장암에서그효과가인정되었다.
mau A B C Qsepharose051229manual001:1_UV@01,SHFT Qsepharose051229manual001:1_Conc Qsepharose051229manual001:1_Fractions Qsepharose051229manual001:1_Inject Manual run 3:1_UV@01,SHFT Manual run 3:1_Fractions
<32303136B3E220BCF6C1B7B1B8BAB4C1F6C4A72D56312E687770>
2016년도 수족구병 관리 지침 목 차 PART Ⅰ. 총 론 1. 개 요 2 2. 수행 체계 3 3. 임상감시 5 4. 실험실 감시 9 5. 역학조사 11 6. 실험실 검사 의뢰 12 7. 환자관리 13 PART Ⅱ. 각 론 1. 개요 17 2. 병원체 18 3. 발생 현황 및 역학적 특징 19 4. 임상 양상 24 5. 진단 및 실험실 검사 27 6.
Minimally invasive parathyroidectomy
2013. 2. 2 대한간암연구학회 7차 심포지움 및 학술대회 Indication and Clinical Outcomes of Metachronous HCC Metastasectomy Shin Hwang Division of Liver Transplantation and Hepatobiliary Surgery, Department of Surgery, Asan
<4D F736F F F696E74202D20B9D9C0CCBFC0C0C7BEE0C7B0C7D05F37B0AD5FC7D7C3BCC0C7BEE0C7B0>
10 장. 항체의약품 바이오의약품의실제 단클론항체의약품 미생물면역학전공 (youhee@cha.ac.kr) 2 공부할내용 중요의약품명상품명타겟항원적응증 Adalimumab Humira TNF α 관절염, 척추염, 크론병 Infliximab Remicade TNF α 관절염, 척추염, 크론병 Rituximab Rituxan CD20 비호지킨성림프종 Bevacizumab
레이아웃 1
대한위장관기질종양연구회 01 GIST 06 02 11 03 Imatinib 14 04 05 06 07 Sunitinib 32 40 44 48 GIST 6 01 7 GIST Guide book GIST 8 01 9 GIST Guide book GIST (CT) MRI FDG-PET 10 02 11 GIST Guide book 12 02 (Imatinib)
< DC1BEBCB328B1C7BFEBC0CF2DC0CCB1D9C8A3292E696E6464>
REVIEW Korean J Obstet Gynecol 2011;54(3):127-131 doi: 10.5468/KJOG.2011.54.3.127 pissn 2233-5188 eissn 2233-5196 PROPHYLACTIC ANTIEMETICS THERAPY AGAINST GYNECOLOGIC CANCER CHEMOTHERAPY Keun Ho Lee, MD
<303920BFF8C0FA C0CCC3B5BFEC2DB9DAB9ABC0CE D34342E687770>
대한내과학회지 : 제 82 권제 1 호 2012 http://dx.doi.org/10.3904/kjm.2012.82.1.37 진행성위암환자에서 1차요법으로 FOLFOX-4 병합화학약물치료의효과와안정성 고신대학교의과대학내과학교실 이천우 박무인 박선자 문원 김형훈 이혜원 구기환 김부경 FOLFOX-4 Combination Chemotherapy as a First-line
388 The Korean Journal of Hepatology : Vol. 6. No COMMENT 1. (dysplastic nodule) (adenomatous hyperplasia, AH), (macroregenerative nodule, MR
6 3 2000 ; 387-392 (3) Dysplastic Nodule Young Nyun Park, M.D., Chanil Park, M.D. Department of Pathology, Yonsei University College of Medicine BRIEF HISTORY 56. AST/ALT 72/73 IU/L, total bilirubin 0.7
Çмúº¸°í4Á¤ÁöÇý
병원약사회지 (2018), 제 35 권제 2 호 J. Kor. Soc. Health-syst. Pharm., Vol. 35, No. 2, 177 ~ 183 (2018) Original Article 유방암환자에서의 trastuzumab 주입관련반응발생률및위험인자분석 정지혜 a, 김유진 a, 여미진 a, 박애령 a, 김순주 a, 황보신이 a, 나현오 b, 가톨릭대학교서울성모병원약제부
<30322E20C6AFC1FD30322E20B9DABAB4B9E82E687770>
대한내과학회지 : 제 88 권제 3 호 2015 http://dx.doi.org/10.3904/kjm.2015.88.3.247 특집 (Special Review) - 혈액종양의새로운치료 최근개발된 B- 세포림프종의치료약제 한양대학교의과대학내과학교실혈액종양내과 박병배 Recently Developed Therapeutic Agents for B-cell Non-Hodgkin
γ
경락경혈학회지 Vol.27, No.1, pp.87 106, 2010 Journal of Meridian & Acupoint Dept. of 1 Meridian & Acupoint, 3 Acupuncture & Moxibustion, College of Oriental Medicine, Daejeon University 2 Division of Clinical
untitled
J Lung Cancer 2011;10(1):1-12 Personalized Therapy in Lung Cancer: Focused on Molecular Targeted Therapy Lung cancer is the leading cause of cancer death worldwide, with an overall 5 year survival rate
Jkbcs042.hwp
Invasive Ductal Carcinoma Arising from Axillary Accessory Breast Tae Wan Kim, Sang Wook Kang, Ji Young Park 2, Seung Sang Ko 1, Min Hee Hur 1, Hae Kyung Lee 1, Sung Soo Kang 1, and Jee Hyun Lee 1 Department
제98회 공동 건강교실 - 2005 한국인의 암 - 부인암의 예방과 치료 2005. 4.20 배 덕 수 성균관대 의대 교수 / 삼성서울병원 산부인과 김 병 기 성균관대 의대 교수 / 삼성서울병원 산부인과 목 차 자궁경부암의 예방과 치료 (강연 : 배덕수( 裵 悳 秀 ) 삼성서울병원 산부인과 교수) Ⅰ. 자궁경부암의 소개 Ⅱ. 자궁경부암의 원인 Ⅲ. 자궁경부암의
아바스틴 (Avastin), 시람자 (Cyramza) 와맞먹는가능성이보인다 아파티닙 의경쟁약물은로슈社의매출 8 조의약품 아바스틴 (Avastin) 및앞으로 아바스틴 을넘어설것으로예상되는릴리社의 시람자 (Cyramza) 다. 세개약물이모두유사하게 VEGF 를타겟으로하기때
(283) Analyst 오병용 2) 79-2621 byoh@taurus.co.kr 글로벌블록버스터 (1 조매출 ) 신약이한국에서나온다 218 년 3 월 21 일 투자의견 N.R.(Initiate) 목표주가 - 현재주가 (3 월 2 일 ) 48,5 원 Upside - KOSDAQ 시가총액 ( 보통주 ) 발행주식수 액면가 자본금 89.4pt 1,765 십억원
ca
Towards Global Eminence Renal Cancer Kidney Transplant JIA LEE College of Nursing Science Kyung Hee University 1 Contents Kidney Cancer Risk factor Symptom Diagnosis Treatment Nursing Kidney Transplantation
(M/49)
Trans-arterial Chemotherapy for advanced HCC 가톨릭의대소화기내과 배시현 간암은진행된병기에서발견되는경우가많다 2004 국립암센터 I 6.5% II 20.1% III 30.9% IVa 25.2% IVb 17.3% 난치성진행성간암 가톨릭 Tx? TAC 계명대 TAC + others conservative 고대 순천향 아주대 6
MHC T cell Receptor Antigen Antigen-presenting cell Antigen-reactive T cell CD28 B7 Activation (proliferation Cytokine production Cytotoxicity) Antigen-presenting cell Antigen-reactive T cell Dormant State
이영주.hwp
지원연구분야 ( 코드 ) G0205 과제번호 1210500 창의일반과제프로그램공개가능여부과제성격 ( 기초, 응용, 개발 ) 응용실용화대상여부실용화비공개 ( 공개, 비공개 ) ( 국문 ) 비소세포폐암환자에서 matrix-assisted laser desorption 연구과제명 과제책임자 세부과제 ionization-time of flight mass spectrometry
번역 Lab Med Online Vol. 5, No. 1: 44-54, January 임상화학 동반생물학적표지자 : 개인맞춤암치료를향한경로제공 Companion Biomarkers: P
번역 Lab Med Online Vol. 5, No. 1: 44-54, January 2015 임상화학 동반생물학적표지자 : 개인맞춤암치료를향한경로제공 Companion Biomarkers: Paving the Pathway to Personalized Treatment for Cancer Michael J. Duffy 1,2, John Crown 3 UCD
원저 ISSN 일산병원학술지 2017;16(2): Epidermal Growth Factor Receptor (EGFR) 변이가있는 70 세이상의고령의진행성 Non-small Cell Lung Cancer (NSCLC) 환자를대상으로 1
원저 ISSN 2093-9272 일산병원학술지 2017;16(2):134-138 Epidermal Growth Factor Receptor (EGFR) 변이가있는 70 세이상의고령의진행성 Non-small Cell Lung Cancer (NSCLC) 환자를대상으로 1 차치료로써 Gefitinib (Iressa ) 단독요법의치료효과및부작용에관한연구 국민건강보험일산병원종양혈액내과
( )Kju269.hwp
만성세균성전립선염모델흰쥐에서 의항염효과 Anti-inflammatory Effect of Lycopene on Chronic Bacterial Prostatitis Rat Model Cho Hwan Yang, Dong Wan Sohn, Yong-Hyun Cho From the Department of Urology, The Catholic University
Very low-risk Low-risk Intermediate-risk High-risk Appendiceal mucinous tumours Mucinous adenoma Mucinou
I. Workshop 결과에대한설문조사결과 A. 종양의행태 (behavior) 코드부여에이견이있는소화기계암에대한설문조사결과 Organ or Subject Stomach Colon Diagnosis 응답자수 ( 총 240 명 ) Low grade adenoma/dysplasia 230 10 0 1 2 3 6 무응답 High grade adenoma/dysplasia
<B0E6C8F1B4EBB3BBB0FA20C0D3BBF3B0ADC1C E687770>
심전도연수강좌 : 처음시작하는사람들을위한심전도 연세대학교원주의과대학순환기내과학교실 안민수 Cardiac Electrophysiology I : Automaticity : 60-100 회 /min, His bundle : 40-60 회 /min Bundle branch : 20-40 회 /min Purkinje fiber : 20 회 /min Cardiac Electrophysiology
슬라이드 1
인간생명과질병 2016. 5. 13 알기쉬운백혈병 강원대학교의학전문대학원내과학교실혈액종양내과분과이희영 ㄴ 림프구 백혈구 백혈구 적혈구 혈소판 http://www.youtube.com/watch?v=fjoyaaygqfe http://www.youtube.com/watch?v=fjoyaaygqfe http://www.youtube.com/watch?v=fjoyaaygqfe
ePapyrus PDF Document
Introduction 373 374 Definition of Child Abuse 375 376 Current Status of Child Abuse 377 378 Causes of Child Abuse 379 Signs and Sequelae of Child Abuse 380 A B C 381 382 383 384 385 Clinical Evaluation
노인의학200303.PDF
2 1. 2. 1) 2) 3) 3. 4. 1) 2) 3) Microcell 4) 5) 5. 6. 1.. (organism).,...?,??.,. 1935 McCay 27 . 1960 Hayflick. 10 (cytogerontology)... 2. 1),,,,.,,,.. (lipofuscin) (fluidity),., (microvilli)..,, (heat
K O R E A C E N T E R S F O R D I S E A S E C O N T R O L & P R E V E N T I O N PHWR Vol. 5 No. 41 www.cdc.go.kr/phwr 2012 10 12 5 41 ISSN:2005-811X Comparison of drug-susceptibility test to the anti-tuberculosis
최악의암사망률, 폐암 : 발암의원인그리고예방과치료 서론암은현대인의건강한삶을위협하는질환이다. 암은인구 10만명당 153명으로국내에서독보적인사망원인 1위질환으로알려져있다. 이중폐암으로인한사망자는인구 10만명당 35.1명으로성별을불문하고암으로인한사망자중가장큰비중을차지하며,
제 14 회 최악의암사망률, 폐암 : 발암의원인그리고예방과치료 이호영 교수 서울대학교약학대학 학력 1984 이화여자대학교약학전공학사 1986 이화여자대학교약학전공석사 1992 이화여자대학교미생물학전공박사 경력 1992. 3-1995. 6 부산대학교박사후연구원 1995. 8-1997. 4 미국텍사스대 M. D. Anderson 암연구소박사후연구원 1997. 4-1999.
14_김용태_ 수정 완료.hwp
원저 ISSN 2093-9272 일산병원학술지 2018;17(2):75-79 뇌전이된비소세포폐암환자를대상으로 Gefitinib(Iressa) 의치료효과분석 국민건강보험일산병원종양혈액내과 김용태 Effect of Gefitinib with Brain Metastasis from Non Small Cell Lung Cancer (NSCLC) Yong Tai Kim
<30382EC0C7C7D0B0ADC1C22E687770>
대한내과학회지: 제 76 권 제 2 호 2009 의학강좌-개원의를 위한 모범처방(Current Clinical Practice) 간기능검사의 이해와 적용 인제대학교 의과대학 일산백병원 내과학교실 김 경 아 Understanding and application of liver function tests Kyung-Ah Kim, M.D. Department of
May 10~ Hotel Inter-Burgo Exco, Daegu Plenary lectures From metabolic syndrome to diabetes Meta-inflammation responsible for the progression fr
May 10~12 2012 Hotel Inter-Burgo Exco, Daegu Plenary lectures From metabolic syndrome to diabetes Meta-inflammation responsible for the progression from obesity to metabolic syndrome originates in the
20(1)-3(10-3)p fm
한국임상약학회지제 20 권제 1 호 Kor. J. Clin. Pharm., Vol. 20, No. 1. 2010 Aprepitant Regimen 의고용량 Cisplatin 유발오심및구토예방효과 박수진 a 최지선 a 안진석 b 신가영 a 민경아 a 정선영 a 인용원 a 손기호 a a 삼성서울병원약제부, b 삼성서울병원혈액종양내과 (2010 년 3 월 1 일접수
451~
병원약사회지 (2010), 제 27 권제 4 호 J. Kor. Soc. Health-Syst. Pharm., Vol. 27, No. 4, 451 ~ 459 (2010) 학술강좌 항진균제 삼성서울병원약제부 악성종양환자와장기이식환자의증가등에따른면역저하환자의증가와광범위항생제의사용등으로침습성진균감염증의빈도가점차증가하고있다. 그러나침습성진균감염증의높은치사율에비해임상에서사용할수있는항진균제는그항균범위와부작용면에서많은제한점들을가지고있다.
내시경 conference
부울경소화기내시경학회 6월집담회 고신대학교복음병원소화기내과전임의서광일 F/63 CASE C.C) epigastric pain for 2 wks P. I) 2014.04.16 EGD at LMC adm via OPD for further evaluation. P. Hx) CASE HTN/DM/Hepatitis/Tbc (+/+/-/-) S. Hx) N-S ROS)
012~019Çмúº¸°í1ÀåÈ£¼®
병원약사회지 (2013), 제 30 권제 1 호 J. Kor. Soc. Health-Syst. Pharm., Vol. 30, No. 1, 12 ~ 19 (2013) 회원학술보고 Cetuximab 주입관련반응의발생빈도및관련인자분석 서울아산병원약제팀, 이화여자대학교약학대학 a Frequency and Related Factors Analysis of Cetuximab
untitled
異 欄 異 欄.. 1 Natacyn Oph. Suspension 750 mg/15 ml/btl, 5%, 15 ml/btl natamycin 2009/6/4 2009 年 5.. 2 異 Cravit- CDC 500 mg/tab Fluoro-uracil Valeant (5- FU) 1000 mg/20 ml/vial levofloxacin 療 TB Cravit-CDC